These findings are consistent with the findings of our study showing that after IL-22BP was administered in vivo, BBB integrity in T2DM model mice improved, EB extravasation decreased, EB content decreased, the expression of IL-22 and inflammatory factors decreased, spatial memory and exploratory behavior significantly improved, etc., and that the proinflammatory effect of IL-22 was inhibited by IL-22BP. The gene discussed is IL22; the disease is type 2 diabetes mellitus.